Medical technology firm Trivitron Healthcare's arm Labsystems Diagnostics has entered into an alliance with Japan-based Shimadzu Corporation for clinical diagnostics in the area of newborn screening.
The companies will cooperate to leverage Labsystems' reagent technology and Shimadzu's instrumentation to detect disorders in newborns rapidly and more precisely, Trivitron Healthcare said in a statement.
Shimadzu and Labsystems Diagnostics will create a winning combination improving access and affordability for newborn screening solutions across the globe, Trivitron Group of Companies Chairman & MD GSK Velu said.
Also Read
"Right now, we are looking at the US, Europe and Japan for this," Velu told PTI.
Newborn screening is a preventive pediatric screening service to assess the occurrence of genetic metabolic disorders, the statement said.
"The agreement between Shimadzu Corporation and Labsystems Diagnostics will help to change the way in newborn screening programmes," Shimadzu Corporation Analytical & Measuring Instruments Division General Manager, Shuzo Maruyama said, adding that it can be made better by expanding the screening capability with detailed analytics and actionable data, thereby providing a new solution for faster, confident diagnosis.
Disclaimer: No Business Standard Journalist was involved in creation of this content
